18F-AV-45 Amyloid PET Imaging in Primary Progressive Aphasia - Florbetapir Amyloid PET Imaging in Focal Dementia Syndromes

Avid Radiopharmaceuticals, Inc.0 个研究点目标入组 23 人开始时间: 2011年8月1日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•1. Are currently enrolled in the longitudinal study of frontotemporal lobular degeneration at the Dementia Research Centre (DRC) at UCL
•2. Patients with PPA will have undergone detailed neuropsychological assessments and will be classified in one of three syndromic groups:PNFA, LPA, or SD
•3. Can tolerate a PET scan procedure
•PCA-AD Group
•1. Are currently enrolled in the longitudinal study of frontotemporal lobular degeneration at the Dementia Research Centre (DRC)
•2. Patients with PCA-AD will have undergone detailed neurological assessments and will fulfil the following criteria: 1) insidious onset of cognitive decline, sufficient to interfere with activities of daily living, with absence of structural lesion or significant whilte matter disease on MRI. 2) relatively preserved episodic memory; deficits on standard psychological testing in at least two of four posterior cortical functions: (a) object perception (b) space perception (c) calculation (d) spelling
•3. can tolerate a PET scan procedure
•Cognitively normal group
•1. have no cognition complaints
•2. are between 55 and 90 years of age
•3. give informed consent
•4. can tolerate a PET scan procedure
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 25

•1. Have clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances
•2. Have a clinically significant cardiovascular disease
•3. Have a clinically significant infectious disease
•4. Have a history of alcohol or substance abuse or dependence
•5. Have a history of severe drug allergy or hypersensitivity
•6. Women of child bearing potential

发起方